Acino ? Delivering Health

More documents

Recommendations

Info

Acino Switzerland: Product Portfolio Brand name* Active ingredient/ Dosage form Basic registration Pain FENTAVERA Fentanyl/TDS EU OXYCONICA BUVERA HYDRONICA Oxycodone/MUPS tablet EU Buprenorphine/TDS EU Hydromorphone/CR capsule EU PARACONICA Paracetamol/solution for i.v. perfusion EU/CH Oncology GOSACIN Goserelin/Implant CH ZOLACIN Zolendronic acid/solution for i.v. perfusion EU/CH * Might be subject to local/regional adaption. Acino respects the property rights of third parties, therefore developments and products are only offered under the condition that they are not in violation of third-party rights or only in countries where such rights do not apply. 44
Acino Switzerland: Product Portfolio (cont’) Active ingredient/Dosage form Basic registration Cardiovascular CLOPACIN Clopidogrel/Film tablet CH Urology Anti-Mycotic CNS GI Vitamins&Co Brand name* METRACIN AMLOCIM NEBIVACIN DOXACIN FUZOCIM ITRACIM LEVACIN PANTOCIM ESPRACIM I.V. FERRACIN I.V: Metoprolol (-succinate)/MUPS SR tablet CH Amlodipine (-besylate)/Tablet CH Nebivolol/Tablet CH Doxazosine/SR tablet CH Alfuzosine/SR tablet CH Itraconazole/Capsule CH Levodopa/Carbidopa/SR tablet CH Pantoprazole/Powder for solution (i.v.) EU/CH Esomeprazole/Powder for solution (i.v.) Iron-Suc./Solution for i.v. perfusion * Might be subject to local/regional adaption. **Brand names still tbd. Acino respects the property rights of third parties, therefore developments and products are only offered under the condition that they are not in violation of third-party rights or only in countries where such rights do not apply. EU EU 45
Page 1 and 2: Acino - Delivering Health Investor
Page 3 and 4: Acino - drug delivery specialist, m
Page 5 and 6: Acino’s growth drivers Fully expl
Page 7 and 8: Technology platform Oral modified r
Page 9 and 10: Oral modified release forms MUPS (M
Page 11 and 12: Technology platform Oral dispersibl
Page 13 and 14: Technology platform Transdermal sys
Page 15 and 16: Transdermal systems Why transdermal
Page 17 and 18: Technology platform Extended releas
Page 19 and 20: Extended release parenterals Advant
Page 21 and 22: Development projects Ferrous sulfat
Page 23 and 24: Development projects Rivastigmine T
Page 25 and 26: Development projects Goserelin & le
Page 27 and 28: Development projects Goserelin 1 &
Page 29 and 30: Development projects Leuprorelin 1
Page 31 and 32: Acino’s development pipeline Stat
Page 33 and 34: Acino - Delivering Health Thank you
Page 35 and 36: Entering emerging markets / “Swis
Page 37 and 38: Acino Switzerland 2009 BtC markets
Page 43: Opportunities Products with added v
Page 47 and 48: Acino portfolio Roll-out in new ter
Page 49 and 50: Criteria for selecting products for
Page 51 and 52: Acino’s business model (example)
Page 53 and 54: Optimized BtB Concept - Geographica
Page 55 and 56: Technical Marketing and Operations:
Page 57 and 58: Acino’s production importance Tec
Page 59 and 60: Production Technologies: Value for
Page 61 and 62: Pellets Innovative technologies for
Page 63 and 64: Pellet Projects High volume project
Page 65 and 66: Granulates Hot melt granulation Sp
Page 67 and 68: Manufacturing Process 67
Page 70 and 71: Implants Implant manufacturing capa
Page 72 and 73: Opportunity: High Quality Service S
Page 74 and 75: Summary Focus on niche technologies
Page 76 and 77: Competitive advantage factor: HighT
Page 78 and 79: Micro Error Tracking System (METS)
Page 80 and 81: Strategy to cope with declining mar
Page 82 and 83: Financials Robert Schmid, Head of I
Page 84 and 85: Promising potential areas of synerg
Page 86 and 87: Reduced currency exposure Mepha / C
Page 88 and 89: Summary and strategy Peter Burema,
Page 90 and 91: Acino’s growth drivers Fully expl
Page 92 and 93: Geographic break-down of revenue DE
Page 94:
Acino - Delivering Health Thank you
show all

Acino ? Delivering Health

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?